. Author manuscript; available in PMC: 2022 Jan 1.

Published in final edited form as: Transplantation. 2021 Jan 1;105(1):170–176. doi: 10.1097/TP.0000000000003502

Table 3.

Association of lymphocyte-depleting agents and maintenance steroids with early kidney transplant outcomes in the prepandemic and pandemic eras

Exposure	Outcome	aOR/aHR		Interaction p
		Prepandemic era	Pandemic era
Lymphocyte-depleting agent (vs. nondepleting agent or no induction)	Rejection, during admission	_0.270.39_0.58	_0.110.23_0.47	0.2
	Delayed graft function	_0.800.95_1.12	_0.691.12_1.80	0.5
	Graft failure, death-censored	_0.710.91_1.16	_0.050.22_1.07	0.1
	Death	_0.820.96_1.14	_0.130.47_1.66	0.3
Maintenance steroid (vs. early steroid withdrawal)	Graft failure, death-censored	_0.710.93_1.23	_0.230.72_2.29	0.7
Maintenance steroid (vs. early steroid withdrawal)	Death	_0.941.23_1.60	_0.280.75_2.04	0.4

aOR, adjusted odds ratio (for rejection and delayed graft function); and aHR, adjusted hazard ratio (for graft failure and death). Interaction p<0.05 indicates statistically significant difference in aOR/aHR between the prepandemic and pandemic eras. Rejection during admission and delayed graft function may occur before the selection of maintenance steroid versus early steroid withdrawal, and therefore were not studied as outcomes for maintenance steroid.